부산대학교 도서관

Comments on the decision of the Strasbourg Court of First Instance in SAS Laboratoires Negma v SAS Biogaran on whether to grant a preliminary injunction against a generic pharmaceuticals manufacturer where patent infringement was alleged and revocation proceedings had been commenced. Considers whether the allegations of infringement were plausible, or the patent was obviously invalid. Compares decisions of the French courts in Lyons and Paris and judgments from Germany and the UK under Directive 2004/48 (Intellectual Property Rights Enforcement Directive) art.9.